Juvenile Localized Scleroderma: Updates and Differences from Adult-Onset Disease

Area of Science:

• Pediatric rheumatology
• Dermatology
• Immunology

Background:

• Children and adolescents with localized scleroderma (LS) face high risks of extracutaneous functional impairment, including hemiatrophy, arthropathy, seizures, and vision loss.
• Pediatric LS is associated with poorer outcomes compared to adult-onset LS, featuring more prevalent extracutaneous involvement (especially in linear scleroderma), increased disease relapses, and longer duration.
• Extracutaneous manifestations significantly impact quality of life and long-term health in pediatric patients.

Purpose of the Study:

• To review recent advancements in the assessment and treatment of localized scleroderma in children and adolescents.
• To enhance understanding of the key pathogenic pathways involved in pediatric localized scleroderma.
• To highlight the importance of early and effective management strategies for improving patient outcomes.

Main Methods:

• Literature review of recent studies on pediatric localized scleroderma.
• Analysis of current treatment strategies and their efficacy.
• Exploration of emerging research on disease mechanisms.

Main Results:

• Consensus among pediatric rheumatologists supports the use of systemic immunosuppressants for high-risk patients, leading to improved outcomes.
• Recent progress has been made in diagnostic and therapeutic approaches.
• Enhanced understanding of disease pathways is guiding new treatment developments.

Conclusions:

• Systemic immunosuppressant therapy has significantly improved outcomes for pediatric localized scleroderma patients at risk of morbidity.
• Continued research into assessment, treatment, and disease pathways is crucial for further improving the management of pediatric LS.
• Early intervention and tailored treatment strategies are vital for mitigating long-term functional impairment.